OncoMatch/Clinical Trials/NCT04583254

Hypofractionated External-beam RadiOtherapy for Intact Cervical Cancer (HEROICC-Trial): A Feasibility Study

Is NCT04583254 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Concurrent Chemotherapy for cervical cancer.

Phase 2RecruitingLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sNCT04583254Data as of May 2026

Treatment: Concurrent Chemotherapy — External radiation given in 25 fractions or so together with weekly chemotherapy and followed by 3 or 4 fractions of brachytherapy is the standard of care for patients with locally advanced cervical cancer. This study investigates the role of shortened external radiotherapy regimen (hypofractionated radiotherapy) by randomizing patients to this experimental regimen versus the standard of care.The purpose of this study is to access the feasibility of patient accrual to this trial in the Canadian setting and to provide an initial evaluation of cancer response and treatment tolerability.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Disease stage

Required: Stage IA, IIA, IIB, IIIC1

Excluded: Stage IIIA, IIIB, IIIC2, IVA, IVB

Performance status

ECOG 0–3(Limited self-care)

Prior therapy

Cannot have received: radiation therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify